BRICANYL
LOE ApproachingNDAINHALATIONAEROSOL, METERED
Approved
Mar 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRICANYL (terbutaline) is a small-molecule beta-2 agonist inhaled as a metered-dose aerosol, indicated for bronchospasm relief in respiratory conditions such as asthma and COPD. It functions as a rapid-acting bronchodilator that relaxes airway smooth muscle to restore airflow. The drug has been a foundational therapy in respiratory care since its 1985 approval.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30), team size is likely contracting and career focus shifts to defending market share rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3
Started Mar 2015
95 enrolled
Asthma
Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients
Started Sep 2009
66 enrolled
Exercise Induced Asthma
Career Relevance
Working on BRICANYL offers limited career advancement opportunity given its LOE-approaching status and zero linked job openings. Roles focus on defensive brand management and maintaining market presence rather than growth initiatives, making this assignment valuable primarily for legacy product expertise.
Worked on BRICANYL at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.